Global Dilated Cardiomyopathy Therapeutics Market Outlook 2021: Global Opportunity and Demand Analysis, Market Forecast, 2022-2030

The dilated cardiomyopathy therapeutics market is anticipated to grow at a CAGR of nearly 3.6% during the forecast period. The main factors contributing to the expansion of the dilated cardiomyopathy therapeutics market are increasing anticipation and the increasing prevalence of heart problems. Furthermore, the increasing number of individuals affected by heart muscle infections, alongside drug or alcohol abuse, is also the main factor that helps in driving the expansion of the market. As the incidence of cardiovascular diseases is increasing, which is directly proportional to the market growth. Whereas the side effects of dilated cardiomyopathy therapeutics that cause severe discomfort to patients are limiting the market growth.

Top Driver: Growing demand for ready-to-eat food will drive the markets growth.
Rising incidences of congestive coronary failure across the world may be a prominent growth driver for the dilated cardiomyopathy therapeutics market as DCM is one of the leading causes of coronary failure. Globally, dilated cardiomyopathy accounts for about 30% to 40% of the entire congestive coronary failure cases annually. Due to the alarming rise in incidences of congestive coronary failure, several companies have initiated clinical test studies to develop therapeutics specifically for dilated cardiomyopathy. Array BioPharma, for example, is conducting a phase II clinical trial study for its drug candidate ARRY-371797 for DCM treatment in 2015.Additionally, Celladon Corporation in 2014 completed its phase II clinical trial study of MYDICAR for dilated cardiomyopathy treatment. The success of those clinical studies will boost the expansion and demand for the dilated cardiomyopathy therapeutics market in the forthcoming years. However, promising gene therapy and the availability of implantable devices (implantable cardioverter defibrillators (ICDs), heart pumps, and pacemakers) are significant market restraints for DCM therapeutics.
Angiotensin II receptor blockers are predicted to dominate the expansion of the market.
Angiotensin II receptor blockers acquire the most important market share, followed by beta-blockers. This is often attributed to the high demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions. Aldosterone antagonists recorded a high rate of growth thanks to the identified positive impact of aldosterone antagonists when utilized in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne dystrophy (DMD). Approval for this indication would further accelerate the general sales of aldosterone antagonists, which successively would positively impact market growth. The other driving factors of the segment are also associated with the increasing prevalence of heart diseases. Therefore, because the prevalence of heart diseases increases, the markets expansion increases too.

North America Dominates the Market and is Expected to Grow in the Forecast Period.
Throughout the forecast period, North America is predicted to dominate the general dilated cardiomyopathy therapeutics market. The expansion is thanks to the rising incidence of cardiovascular diseases, well-established insurance policies, and the availability of advanced healthcare infrastructure, which are the main factors.
In the North American region, the U.S. holds the most important market share thanks to factors like an increasing number of geriatric populations and a growing number of heart diseases within the country, which are anticipated to stimulate the demand in this region. Therefore, because the number of cardiovascular diseases increases, the marketplace for dilated cardiomyopathy also increases.

Players to Focus on Dilated Cardiomyopathy Therapeutics Market

Key players within the global DCM market include
Array BioPharma, Inc.,
AstraZeneca plc,
Celladon Corporation,
GlaxoSmithKline plc,
Janssen Pharmaceuticals, Inc.,
Merck & Co., Inc.,
Novartis International AG,
Pfizer, Inc.,
Sanofi S.A.,
Teva Pharmaceutical Industries Ltd.
Vericel Corporation


Scope of the Report

By Drug
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers

By Pipeline
ARRY-797
ixCELL-DCM
MYDICAR

By Region
North America
Europe
Asia Pacific
Rest Of World


Key Reasons to Purchase this Report
1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders a definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.

Chapter 1 Overview And Scope
1.1 Market Vision
1.1.1 Market Definition
1.1.2 Market Scope
1.2 Market Segmentation

Chapter 2 Our Research Practice
2.1 Our Research Methodology
2.2 Data Triangulation
2.3 Data Sources
2.4 Assumptions for the study
2.5 Approach Adopted

Chapter 3 Executive Summary
3.1 Market Snapshot
3.2 Regional Snapshot
3.3 Segment Summary

Chapter 4 Covid-19 Impact Analysis
4.1 Overview
4.2 Prevalence analysis
4.3 Key Factor Impact Analysis

Chapter 5 Global Dilated Cardiomyopathy Therapeutics Market Forces
5.1 Whats Driving the Market
5.2 Porters Five Forces Analysis
5.2.1 Power of Suppliers
5.2.2 Threats From New Entrants
5.2.3 Power of Buyer
5.2.4 Threat From Substitute Product
5.2.5 Degree of Competition

Chapter 6 Global Dilated Cardiomyopathy Therapeutics Market -Industry Snapshots
6.1 Overview
6.1.1 Global Dilated Cardiomyopathy Therapeutics Market Value, 2019 - 2028, (US$ Bn)
6.2 Market Overview
6.2.1 Drivers Analysis
6.2.2 Restraint/Challenges analysis
6.2.3 Opportunity Analysis
6.3 Supply Chain/Value Chain Analysis
6.4 Market SWOT Analysis

Chapter 7 Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Drug
7.1 Overview
7.2 Key Findings for Dilated Cardiomyopathy Therapeutics Market- By Drug
7.2.1 Dilated Cardiomyopathy Therapeutics Market- Aldosterone antagonists
7.2.2 Dilated Cardiomyopathy Therapeutics Market- Angiotensin-converting enzyme (ACE) inhibitors
7.2.3 Dilated Cardiomyopathy Therapeutics Market- Angiotensin II receptor blockers (ARBs)

Chapter 8 Global Dilated Cardiomyopathy Therapeutics Market Analysis, by Pipeline
8.1 Overview
8.2 Key Findings for Dilated Cardiomyopathy Therapeutics Market- By Pipeline
Dilated Cardiomyopathy Therapeutics Market- ARRY-797 Dilated Cardiomyopathy Therapeutics market by Pipeline 1, 2019 - 2028 (USD Million)
8.2.1 Dilated Cardiomyopathy Therapeutics Market- polyethylene terephthalate (pet)
8.2.2 Dilated Cardiomyopathy Therapeutics Market- ixCELL-DCM
Dilated Cardiomyopathy Therapeutics market by Product Type 3, 2019 - 2028 (USD Million)
8.2.3 Dilated Cardiomyopathy Therapeutics Market- MYDICAR
Dilated Cardiomyopathy Therapeutics market by Pipeline 4, 2019 - 2028 (USD Million)

Chapter 9 Dilated Cardiomyopathy Therapeutics Market Analysis by Region
9.1 Key Findings for Dilated Cardiomyopathy Therapeutics Market- By region
9.2 Overview
9.2.1 Global Dilated Cardiomyopathy Therapeutics Market Analysis, By Type, 2019 - 2028
9.2.2 Global Dilated Cardiomyopathy Therapeutics Market Analysis, By Product Type, 2019 - 2028
9.3 Dilated Cardiomyopathy Therapeutics Market North America
9.3.1 Overview
9.3.2 U.S.
9.3.3 Canada
9.3.4 Mexico
9.3.5 North America Market, By Type
9.3.6 North America Market, By Product Type
9.4 Dilated Cardiomyopathy Therapeutics Market Europe
9.4.1 Overview
9.4.2 Germany
9.4.3 United Kingdom
9.4.4 France
9.4.5 Italy
9.4.6 Rest Of Europe
9.4.7 Europe Market, By Type
9.4.8 Europe Market, By Product Type
9.5 Dilated Cardiomyopathy Therapeutics Market Asia Pacific
9.5.1 Overview
9.5.2 China
9.5.3 Japan
9.5.4 India
9.5.5 Rest of APAC
9.5.6 Asia Pacific Market, By Type
9.5.7 Asia Pacific Market, By Product Type
9.6 Dilated Cardiomyopathy Therapeutics Market Rest Of World
9.6.1 Overview
9.6.2 Middle East & Africa (MEA)
9.6.3 South America
9.6.4 Rest Of World
9.6.5 South America, Middle East and Africa Market, By Type
9.6.6 South America, Middle East and Africa Market, By Product Type

Chapter 10 Market Competition Analysis
10.1 Market Share/Positioning Analysis
10.1.1 Market Positioning of Key Vendors, 2019
10.1.2 Key Strategies Adopted by the Leading Players
10.1.3 Recent Developments

Chapter 11 Company Profiles- Snapshot
11.1 Vericel Business Fundamentals
11.1.1 Financial Snapshots
11.1.2 Product Portfolio
11.1.3 Recent Developments
11.2 Array BioPharma, Inc.,
11.3 AstraZeneca plc,
11.4 Celladon Corporation,
11.5 GlaxoSmithKline plc,
11.6 Janssen Pharmaceuticals, Inc.,
11.7 Merck & Co., Inc.,
11.8 Novartis International AG,
11.9 Pfizer, Inc.,
11.10 Sanofi S.A.,
11.11 Teva Pharmaceutical Industries Ltd.
*More than 10 Companies are profiled in this Research Report*
*Financials would be provided on a best efforts basis for private companies

Chapter 12 Appendix


List Of Tables

TABLE 1 Dilated Cardiomyopathy Therapeutics market by Drug 1, 2019 - 2028 (USD Million)
TABLE 2 Dilated Cardiomyopathy Therapeutics market by Drug 2, 2019 - 2028 (USD Million)
TABLE 3 Dilated Cardiomyopathy Therapeutics market byDrug 3, 2019 - 2028 (USD Million)
TABLE 4 Dilated Cardiomyopathy Therapeutics market by Pipeline 2, 2019 - 2028 (USD Million)
TABLE 5 Global Dilated Cardiomyopathy Therapeutics Market Value, By Type, 2019 - 2028 (US$ Bn)
TABLE 6 Global Dilated Cardiomyopathy Therapeutics Market Value, By Product Type, 2019 - 2028 (US$ Bn)
TABLE 7 Dilated Cardiomyopathy Therapeutics Market Analysis by North America (USD Million), 2019 - 2028
TABLE 8 U.S. Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 9 U.S. Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 10 U.S. Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 11 Canada Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 12 Canada Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 13 Canada Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 14 Mexico Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 15 Mexico Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 16 Mexico Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 17 Dilated Cardiomyopathy Therapeutics Market Analysis by Europe (USD Million), 2019 - 2028
TABLE 18 Germany Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 19 Germany Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 20 Germany Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 21 United Kingdom Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 22 United Kingdom Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 23 United Kingdom Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 24 France Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 25 France Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 26 France Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 27 Italy Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 28 Italy Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 29 Italy Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 30 Rest Of Europe Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 31 Rest Of Europe Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 32 Rest Of Europe Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 33 Dilated Cardiomyopathy Therapeutics Market Analysis by Asia Pacific (USD Million), 2019 - 2028
TABLE 34 China Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 35 China Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 36 China Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 37 Japan Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 38 Japan Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 39 Japan Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 40 India Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 41 India Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 42 India Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 43 Rest of APAC Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 44 Rest of APAC Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 45 Rest of APAC Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 46 Dilated Cardiomyopathy Therapeutics Market Analysis byRest Of World(USD Million), 2019 - 2028
TABLE 47 Middle East & Africa (MEA) Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 48 Middle East & Africa (MEA) Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 49 Middle East & Africa (MEA) Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 50 South America Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 51 South America Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 52 South America Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
TABLE 53 Rest Of World Dilated Cardiomyopathy Therapeutics Market, 2019 - 2028 (USD Million)
TABLE 54 Rest Of World Dilated Cardiomyopathy Therapeutics Market, By Type, 2019 - 2028 (USD Million)
TABLE 55 Rest Of World Dilated Cardiomyopathy Therapeutics Market, By Product Type, 2019 - 2028 (USD Million)
Chapter 1

List Of Figures

FIG. 1 Global Dilated Cardiomyopathy Therapeutics : Market Segmentation
FIG. 2 Global Dilated Cardiomyopathy Therapeutics Market: Research Methodology
FIG. 3 Top-Down and Bottom Up Approach
FIG. 4 Market Snapshot
FIG. 5 Porters Five Forces Analysis
FIG. 6 Global Dilated Cardiomyopathy Therapeutics Market Value, 2019 - 2028, (US$ Bn)
FIG. 7 Supply Chain/Value Chain Analysis
FIG. 8 Global Dilated Cardiomyopathy Therapeutics Market Value Contribution, By Type, 2019 & 2026 (%)
FIG. 9 Global Dilated Cardiomyopathy Therapeutics Market Value Contribution, By Product Type, 2019 & 2026 (%)
FIG. 10 Global Dilated Cardiomyopathy Therapeutics Market Value, 2019 - 2028, (US$ Bn)
FIG. 11 North America Dilated Cardiomyopathy Therapeutics Market Value, 2019 - 2028, (US$ Bn)
FIG. 12 Dilated Cardiomyopathy Therapeutics Market Segment 1 North America
FIG. 13 Dilated Cardiomyopathy Therapeutics Market Segment 2 North America
FIG. 14 Dilated Cardiomyopathy Therapeutics U.S. outlook, 2019 & 2026
FIG. 15 Dilated Cardiomyopathy Therapeutics Canada outlook, 2019 & 2026
FIG. 16 Dilated Cardiomyopathy Therapeutics Mexico outlook, 2019 & 2026
FIG. 17 Europe Dilated Cardiomyopathy Therapeutics Market Value, 2019 - 2028, (US$ Bn)
FIG. 18 Dilated Cardiomyopathy Therapeutics Market Segment 1 Europe
FIG. 19 Dilated Cardiomyopathy Therapeutics Market Segment 2 Europe
FIG. 20 Dilated Cardiomyopathy Therapeutics Germany outlook, 2019 & 2026
FIG. 21 Dilated Cardiomyopathy Therapeutics United Kingdom outlook, 2019 & 2026
FIG. 22 Dilated Cardiomyopathy Therapeutics France outlook, 2019 & 2026
FIG. 23 Dilated Cardiomyopathy Therapeutics Italy outlook, 2019 & 2026
FIG. 24 Dilated Cardiomyopathy Therapeutics Rest Of Europe outlook, 2019 & 2026
FIG. 25 Asia Pacific Dilated Cardiomyopathy Therapeutics Market Value, 2019 - 2028, (US$ Bn)
FIG. 26 Dilated Cardiomyopathy Therapeutics Market Segment 1 Asia Pacific
FIG. 27 Dilated Cardiomyopathy Therapeutics Market Segment 2 Asia Pacific
FIG. 28 Dilated Cardiomyopathy Therapeutics China outlook, 2019 & 2026
FIG. 29 Dilated Cardiomyopathy Therapeutics Japan outlook, 2019 & 2026
FIG. 30 Dilated Cardiomyopathy Therapeutics India outlook, 2019 & 2026
FIG. 31 Dilated Cardiomyopathy Therapeutics Rest of APAC outlook, 2019 & 2026
FIG. 32 Rest Of World Dilated Cardiomyopathy Therapeutics Market Value, 2019 - 2028, (US$ Bn)
FIG. 33 Dilated Cardiomyopathy Therapeutics Market Segment 1 Rest Of World
FIG. 34 Dilated Cardiomyopathy Therapeutics Market Segment 2 Rest Of World
FIG. 35 Dilated Cardiomyopathy Therapeutics Middle East & Africa (MEA) outlook, 2019 & 2026
FIG. 36 Dilated Cardiomyopathy Therapeutics South America outlook, 2019 & 2026
FIG. 37 Dilated Cardiomyopathy Therapeutics Rest Of World outlook, 2019 & 2026

Companies Mentioned

Zensun (Shanghai) Sci& Tech Co. Ltd.
Aastrom Biosciences
Kasiak Research Pvt. Ltd.
MyoKardia


Global Endocrine Function Market

This new report from provides analysis of the endocrine function diagnostics market, including emerging tests, technologies, instrumentation, sales forecasts, market shares and strategic profiles of leading suppliers.The report is

USD 14500 View Report

Global Coagulation Market Analysis

2022 Global Coagulation Market AnalysisLeading and Emerging Supplier Sales, Shares and Instrument Installed Base by Geographic Region This new report from provides granular data and analysis not available from

USD 4500 View Report

Global Dilated Cardiomyopathy Therapeutic Market Research Report 2019-2023

The high acceptance of angiotensin II receptor blocks is attributed to their effective therapeutic action for the treatment of dilated cardiomyopathy. In the context of China-US trade war and global

USD 2850 View Report

Dilated Cardiomyopathy - Pipeline Review, H1 2019

Dilated Cardiomyopathy - Pipeline Review, H1 2019Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy - Pipeline Review, H1 2019, provides an overview of the Dilated Cardiomyopathy

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available